Tetra Bio Pharma Inc (OTCMKTS:TBPMF) has engaged investor relations firm LifeSci Advisors and a corporate communications firm LifeSci Public Relations. The business guru seeks to make these two of its strategic partners.
The engagement between the parties
LifeSci will pay focus to an investor relations and communications program and will see its proper implement ion nod execution. Under this will be the analyst and investor targeting/outreach, media engagement, and corporate communications. There will also be the non-deal roadshows, Key Opinion Leader (KOL), and social media events.
Tetra’s chief scientific officer who is also its chief executive officer Guy Chamberland says the engagement with LifeSci during is a good thing. Discussions are based on strategies that will help them spark about immense business growth.
The official also speaks about multiple value-creating milestones insisting there is much to do if they have to succeed. He is assertive on the need for them to communicate their overarching value proposition to investors in a clear way. The industry also needs to be aware of everything going on.
According to this official, nothing is as important to them as the achievement of these key inflection points.
Another official working with Tetra Bio Pharma in a recent interview said that everything with LifeSci Advisors commenced August 6, 2019. This engagement was held for over 12 months. LifeSci Advisors will have to be paid for the services it delivers. The total amount will add up to about US$30,000 per month. There will also be a 5% annual increase of the monthly fee as was disclosed by the company official.
A focus into the future
Tetra Bio Pharma says it will continue working closely with its subsidiaries. The business guru will pay more attention to subsidiaries developing Veterinary Products and Bio Pharmaceuticals containing cannabis. It also wants to ensure that all products under its name contain other medicinal plant-based elements.
Some of the parties set to benefit from the progressive moves by the company are physicians, regulators, and insurance companies. Tetra agrees that indeed serving healthcare providers and patients with novel treatments and drugs is a challenging affair. However, it confirms that it will be aggressive to ensure that nothing stops towards the provision of better healthcare services.